Detalles de la búsqueda
1.
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Prostate
; 83(3): 227-236, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36382533
2.
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
Br J Cancer
; 129(2): 291-300, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37208512
3.
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Cancer
; 127(12): 1965-1973, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33690902
4.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
BMC Cancer
; 19(1): 196, 2019 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30832606
5.
Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
Oncology (Williston Park)
; 31(6): 467-74, 2017 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28620903
6.
Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
J Nucl Med
; 65(2): 199-205, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212070
7.
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.
J Nucl Med
; 65(6): 938-943, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697672
8.
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
Cancer Immunol Res
; 12(4): 453-461, 2024 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38276989
9.
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Prostate Cancer Prostatic Dis
; 2024 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38341461
10.
Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects.
Eur Urol Focus
; 9(3): 405-406, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36690547
11.
Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
JCO Oncol Pract
; 19(5): e773-e783, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36649492
12.
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Urol Oncol
; 41(3): 145.e7-145.e15, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36435709
13.
Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
Urol Oncol
; 40(8): 379.e17-379.e24, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35750560
14.
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Cancer Res Commun
; 2(7): 570-576, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36923283
15.
Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer.
JCO Oncol Pract
; 18(5): e648-e658, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34932386
16.
Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Future Oncol
; 12(21): 2393-2396, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27453303
17.
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Clin Cancer Res
; 26(20): 5338-5347, 2020 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32694156
18.
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
Urol Oncol
; 38(12): 931.e9-931.e16, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32624423
19.
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 26(17): 4616-4624, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32727885
20.
Small-cell/neuroendocrine prostate cancer: a growing threat?
Oncology (Williston Park)
; 28(10): 838-40, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25323608